WallStSmart
OCUL

Ocular Therapeutix Inc

NASDAQ: OCUL · HEALTHCARE · BIOTECHNOLOGY

$9.21
-1.18% today

Updated 2026-04-29

Market cap
$2.00B
P/E ratio
P/S ratio
38.59x
EPS (TTM)
$-1.42
Dividend yield
52W range
$6 – $16
Volume
4.9M

Ocular Therapeutix Inc (OCUL) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-9.4%
Last 4 quarters
Revenue YoY growth
-22.4%
Most recent quarter
EPS YoY growth
+0.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+1.0%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+7.1%
2026-02-05
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-05$-0.29+9.4%$8.55$9.16+7.1%
2025-11-04$-0.38-2.7%$11.41$10.81-5.3%
2025-08-05$-0.39-11.4%$12.35$12.50+1.2%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.32$-0.29+9.4%$13.25M-22.4%
2025-09-30$-0.37$-0.38-2.7%$14.54M-5.7%
2025-06-30$-0.35$-0.39-11.4%$13.46M-18.1%
2025-03-31$-0.28$-0.37-33.0%$10.70M-27.6%
2024-12-31$-0.22$-0.29-31.8%$17.08M+15.4%
2024-09-30$-0.24$-0.22+8.3%$15.43M+2.3%
2024-06-30$-0.22$-0.26-18.2%$16.44M+8.3%
2024-03-31$-0.19$-0.70-268.4%$14.77M
2023-12-31$-0.30$-0.35-16.7%$14.80M
2023-09-30$-0.29$-0.17+41.4%$15.08M
2023-06-30$-0.30$-0.26+13.3%$15.19M

Frequently asked questions

Has Ocular Therapeutix Inc beaten earnings estimates?
Ocular Therapeutix Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -9.4% over the last 4 quarters.
How does OCUL stock react to earnings?
OCUL stock has moved an average of +1.0% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Ocular Therapeutix Inc's revenue growth rate?
Ocular Therapeutix Inc reported year-over-year revenue growth of -22.4% in its most recent quarter, with EPS growing +0.0% year-over-year.